- Global Pharma News & Resources

Indication Bioscience Granted First Patent for Statin Plus Cannabidiol (CBD) Combination

Issuance of U.S. Patent US10835501B2 Begins Development of Indication BioSciences’ Intellectual Patent Portfolio for statin plus cannabinoid combination therapies.

SILVERTHORNE, Colo.--(BUSINESS WIRE)--Indication BioScience, an early-stage pharmaceutical development company focused on identifying, developing, and commercializing innovative therapies to address unmet needs in cardiovascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent US10835501B2, which relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis.

According to the CDC, approximately 28% of Americans over forty years of age are prescribed a statin for hypercholesterolemia. Current statin therapies are associated with adverse effects including myalgia. In US clinical practices, roughly 45% of patients discontinue statin use after 6 months use due to adverse effects.

Cannabinoids are a diverse class of small molecules that interact on the g-coupled receptor subtypes CB1 and CB2. Cannabinoids are most commonly associated with the cannabis plant, however now may be produced using traditional small molecule synthesis methods. Findings suggest that cannabinoids such as Cannabidiol in combination with statins decrease the adverse effects of statin drugs while increasing efficacy in treating cardiovascular disease such as hypercholesterolemia.

“We are extremely pleased to have been granted the first patent for our portfolio of cannabinoid-statin combination therapies. This issuance is a first step in the development of our lead drug candidate, the atorvastatin+cannabidiol combination therapy Atorva+. The Atorva+ concept began with observations in the legal medicinal cannabis community, and led us to an understanding of the potential of the combination in the treatment of cardiovascular disease,” said CEO Mathew Sherwood. “

“The clinical implications and potential health outcomes of this combination may be revolutionary in achieving a cost effective alternative for hard to treat lipid abnormalities and improved long term cardiovascular health. Our ongoing pre-clinical research studies are designed to confirm optimal dosing combinations to achieve appropriate outcomes in a global marketplace. The economic advantages are significant and we look for appropriate partners to facilitate our growth,” said President Jim Smeeding R.Ph., MBA.


Mathew D. Sherwood

Editor Details

  • Company:
    • Businesswire
Last Updated: 01-Feb-2021